<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03819088</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00099791</org_study_id>
    <secondary_id>NCI-2017-02467</secondary_id>
    <secondary_id>Winship4173-17</secondary_id>
    <nct_id>NCT03819088</nct_id>
  </id_info>
  <brief_title>Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer</brief_title>
  <official_title>Effects on QOL When Zinc is Supplemented in Patients With Upper GI Cancer on Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study examines how well zinc works in improving quality of life in patients
      with gastrointestinal cancer that cannot be removed by surgery who are receiving
      chemotherapy. Zinc may help to improve patient's quality of life by preventing zinc
      deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. Assess the effects on quality of life (QOL) when supplementing zinc in upper
      gastrointestinal (GI) cancer patients while they are receiving chemotherapy.

      SECONDARY OBJECTIVES:

      I. Correlate hypoalbuminemia with serum zinc deficiency.

      II. Correlate zinc deficiency with neutropenia.

      OUTLINE: Patients are randomized into 1 of 2 groups.

      GROUP I: Patients receive zinc orally (PO) thrice daily (TID) for months 1 and 2 only of the
      first 4 months on therapy.

      GROUP II: Patients receive zinc orally (PO) TID for months 3 and 4 only of the first 4 months
      on therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life scores</measure>
    <time_frame>Up to 4 months after study start</time_frame>
    <description>Quality of life (QOL) will be evaluated through patient subjective responses to the QOL survey.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum zinc level</measure>
    <time_frame>Up to 4 months after study start</time_frame>
    <description>Zinc levels will be monitored monthly with blood tests. Low zinc will be defined as under 60 mcg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum albumin level</measure>
    <time_frame>Up to 4 months after study start</time_frame>
    <description>Albumin levels will be monitored monthly with blood tests. Low albumin will be defined as under 3.5 gm/dl.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Gastric Carcinoma</condition>
  <condition>Liver and Intrahepatic Bile Duct Carcinoma</condition>
  <condition>Unresectable Esophageal Carcinoma</condition>
  <condition>Unresectable Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group I (zinc months 1 and 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive zinc PO TID for months 1 and 2 only of the first 4 months on therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (zinc months 3 and 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive zinc PO TID for months 3 and 4 only of the first 4 months on therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (zinc months 1 and 2)</arm_group_label>
    <arm_group_label>Group II (zinc months 3 and 4)</arm_group_label>
    <other_name>Zinc sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who present to adult medical oncology outpatient clinic with new diagnosis of
             non-resectable gastric, gastro-esophageal, pancreas or biliary cancer

          -  Patients plan to receive chemotherapy at an Emory Cancer Center

          -  No prior chemotherapy or radiation therapy for newly diagnosed gastric,
             gastro-esophageal, pancreas or biliary cancer

          -  Patients must sign informed consent

        Exclusion Criteria:

          -  Zinc supplementation is not indicated for pregnant or lactating women therefore, this
             is an exclusion criteria and women of childbearing age will complete a pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edith Brutcher, MSN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edith Brutcher, MSN</last_name>
    <phone>404-778-2670</phone>
    <email>edith.brutcher@emoryhealthcare.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheena Abraham</last_name>
      <phone>404-778-2670</phone>
      <email>sheena.abraham@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tyra Gaines</last_name>
      <phone>404-712-3308</phone>
      <email>tgaine3@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Emory Saint Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Escobar</last_name>
      <phone>678-843-7029</phone>
      <email>alicia.m.escobar@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pam Bourbo, RN, MPH</last_name>
      <phone>678-843-6875</phone>
      <email>pamela.bourbo@emory.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Edith Brutcher</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Plan may be reevaluated at the time of publication.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

